Phosphatase inhibitors block in vivo binding of peptides to class I major histocompatibility complex molecules.
Class I major histocompatibility complex (MHC) molecules are heterotrimers of heavy chains, beta 2-microglobulin, and 8-10 amino acid-long peptides. Assembly of class I MHC molecules into complexes which are stable and can be transported to the cell surface occurs soon after insertion of individual subunits into the endoplasmic reticulum (ER). To identify subcellular compartments required for class I MHC assembly, we studied class I biosynthesis in human cell lines treated with several inhibitors of intracellular transport. We found that HLA-B701 molecules do not assemble in CIR transfectants in which a block in protein transport from the ER is established by treatment with phosphatase inhibitors. In contrast, stable HLA-B701 complexes form in cells in which the ER becomes mixed with the Golgi after treatment with brefeldin A. Neither treatment impaired binding of HLA-B701 to the ER-resident protein calnexin, and unassembled heavy chains in phosphatase-inhibited cells showed prolonged association with calnexin. In addition, the mouse class I molecule H-2Db, which binds beta 2-microglobulin in human T2 cells in the absence of transporter of antigenic peptides, formed complexes in CIR cell transfectants treated with phosphatase inhibitors. Taken together, these data demonstrate that phosphatase inhibitors do not prevent assembly of class I heavy chain beta 2-microglobulin dimers, but instead interfere with peptide loading. These results are consistent with the possibility that class I MHC molecules are transported from their initial site of insertion into the rough ER before binding peptides, or alternatively that peptide loading mediated by transporter of antigenic peptides is blocked by phosphatase inhibitors.
Tector
M
M
Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania 15261.
Zhang
Q
Q
Salter
R D
RD
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D001692:Biological Transport / Q000187:drug effects; D020126:Brefeldin A; D002193:Cantharidin / Q000494:pharmacology; D002451:Cell Compartmentation; D003517:Cyclopentanes / Q000494:pharmacology; D004721:Endoplasmic Reticulum / Q000378:metabolism; D004988:Ethers, Cyclic / Q000494:pharmacology; D006183:H-2 Antigens / Q000378:metabolism; D015235:HLA-B Antigens / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D051379:Mice; D019319:Okadaic Acid; D010455:Peptides / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors*; D011134:Polysaccharides / Q000096:biosynthesis; D011485:Protein Binding / Q000187:drug effects; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D000511:alpha-Macroglobulins / Q000378:metabolism
D003517:Cyclopentanes; D004988:Ethers, Cyclic; D006183:H-2 Antigens; D015235:HLA-B Antigens; D015395:Histocompatibility Antigens Class I; D010455:Peptides; D011134:Polysaccharides; D000511:alpha-Macroglobulins; D019319:Okadaic Acid; D020126:Brefeldin A; D010744:Phosphoric Monoester Hydrolases; D002193:Cantharidin